Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Myelodysplastic Syndrome: Diagnosis and Screening
share announcement

Myelodysplastic Syndrome: Diagnosis and Screening

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 30631

Special Issue Editor

Prof. Dr. Valerie Bardet

E-Mail Website
Guest Editor
Service d’Hématologie-Immunologie-Transfusion, CHU Ambroise Paré, INSERM UMR 1184, AP-HP, Université Paris Saclay, 92100 Boulogne-Billancourt, France
Interests: myelodysplastic syndromes; acute myeloid leukemia; flow cytometry; morphology; hematology analyzer

Special Issue Information

Dear Colleagues,

Myelodysplastic syndromes are one of the most frequent hematological malignancies, especially in the elderly population. Differential diagnoses in the case of one or several cytopenias are routinely investigated in hematology laboratories. These diagnoses rely first and foremost on the optical microscope (blood and bone marrow smears) and require expertise as some differential diagnosis can be challenging. Of course, the definition of a myelodysplastic syndrome has evolved over time and has also included the karyotype for more than ten years.

In this Special Issue, we will review methods for the diagnosis of myelodysplastic syndromes, focusing on recent advances. Much emphasis will be put on the clinical usefulness in terms of prognostic and theragnostic implications and on the current recommendations from different societies and groups. Original, review, and guidance/guidelines papers are welcome.

Prof. Dr. Valerie Bardet
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • morphology
  • flow cytometry
  • molecular biology
  • cytogenetics
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (8 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

13 pages, 1700 KiB  
Review
When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms
by Sandrine Girard, Franck Genevieve, Emmanuelle Rault, Odile Fenneteau and Jean-François Lesesve
Diagnostics 2022, 12(7), 1752; https://doi.org/10.3390/diagnostics12071752 - 20 Jul 2022
Cited by 3 | Viewed by 4069
Abstract
Ring sideroblasts are commonly seen in myelodysplastic neoplasms and are a key condition for identifying distinct entities of myelodysplastic neoplasms according to the WHO classification. However, the presence of ring sideroblasts is not exclusive to myelodysplastic neoplasms. Ring sideroblasts are as well either [...] Read more.
Ring sideroblasts are commonly seen in myelodysplastic neoplasms and are a key condition for identifying distinct entities of myelodysplastic neoplasms according to the WHO classification. However, the presence of ring sideroblasts is not exclusive to myelodysplastic neoplasms. Ring sideroblasts are as well either encountered in non-clonal secondary acquired disorders, such as exposure to toxic substances, drug/medicine, copper deficiency, zinc overload, lead poison, or hereditary sideroblastic anemias related to X-linked, autosomal, or mitochondrial mutations. This review article will discuss diseases associated with ring sideroblasts outside the context of myelodysplastic neoplasms. Knowledge of the differential diagnoses characterized by the presence of ring sideroblasts in bone marrow is essential to prevent any misdiagnosis, which leads to delayed diagnosis and subsequent management of patients that differ in the different forms of sideroblastic anemia. Full article
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)
►▼ Show Figures

Figure 1

20 pages, 1176 KiB  
Review
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
by Yannick Simoni and Nicolas Chapuis
Diagnostics 2022, 12(7), 1659; https://doi.org/10.3390/diagnostics12071659 - 7 Jul 2022
Cited by 4 | Viewed by 3344
Abstract
Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS [...] Read more.
Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS will strongly increase in the future. Thus, precise diagnosis and evaluation of the progression risk of these diseases are imperative to adapt the treatment. Dysregulations of both innate and adaptive immune systems are frequently detected in MDS patients, and their critical role in MDS pathogenesis is now commonly accepted. However, different immune dysregulations and/or dysfunctions can be dynamically observed during the course of the disease. Monitoring the immune system therefore represents a new attractive tool for a more precise characterization of MDS at diagnosis and for identifying patients who may benefit from immunotherapy. We review here the current knowledge of the critical role of immune dysfunctions in both MDS and MDS precursor conditions and discuss the opportunities offered by the detection of these dysregulations for patient stratification. Full article
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)
►▼ Show Figures

Figure 1

18 pages, 889 KiB  
Review
Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process
by Nathalie Douet-Guilbert, Benoît Soubise, Delphine G. Bernard and Marie-Bérengère Troadec
Diagnostics 2022, 12(7), 1658; https://doi.org/10.3390/diagnostics12071658 - 7 Jul 2022
Cited by 5 | Viewed by 3963
Abstract
Myelodysplastic syndromes (MDS) are considered to be diseases associated with splicing defects. A large number of genes involved in the pre-messenger RNA splicing process are mutated in MDS. Deletion of 5q and 7q are of diagnostic value, and those chromosome regions bear the [...] Read more.
Myelodysplastic syndromes (MDS) are considered to be diseases associated with splicing defects. A large number of genes involved in the pre-messenger RNA splicing process are mutated in MDS. Deletion of 5q and 7q are of diagnostic value, and those chromosome regions bear the numbers of splicing genes potentially deleted in del(5q) and del(7q)/-7 MDS. In this review, we present the splicing genes already known or suspected to be implicated in MDS pathogenesis. First, we focus on the splicing genes located on chromosome 5 (HNRNPA0, RBM27, RBM22, SLU7, DDX41), chromosome 7 (LUC7L2), and on the SF3B1 gene since both chromosome aberrations and the SF3B1 mutation are the only genetic abnormalities in splicing genes with clear diagnostic values. Then, we present and discuss other splicing genes that are showing a prognostic interest (SRSF2, U2AF1, ZRSR2, U2AF2, and PRPF8). Finally, we discuss the haploinsufficiency of splicing genes, especially from chromosomes 5 and 7, the important amplifier process of splicing defects, and the cumulative and synergistic effect of splicing genes defects in the MDS pathogenesis. At the time, when many authors suggest including the sequencing of some splicing genes to improve the diagnosis and the prognosis of MDS, a better understanding of these cooperative defects is needed. Full article
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)
►▼ Show Figures

Figure 1

13 pages, 1242 KiB  
Review
The Mesenchymal Niche in Myelodysplastic Syndromes
by Chloé Friedrich and Olivier Kosmider
Diagnostics 2022, 12(7), 1639; https://doi.org/10.3390/diagnostics12071639 - 5 Jul 2022
Cited by 2 | Viewed by 2539
Abstract
Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in [...] Read more.
Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow microenvironment (BMME) in the development of MDSs. The mesenchymal niche represents a key component of the BMME. In this review, we discuss the role of the mesenchymal niche in the pathophysiology of MDS and provide an overview of currently available in vitro and in vivo models that can be used to study the effects of the mesenchymal niche on HSCs. Full article
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)
►▼ Show Figures

Figure 1

8 pages, 706 KiB  
Review
VEXAS Syndrome: A Novelty in MDS Landscape
by Marie Templé and Olivier Kosmider
Diagnostics 2022, 12(7), 1590; https://doi.org/10.3390/diagnostics12071590 - 29 Jun 2022
Cited by 27 | Viewed by 4836
Abstract
Fever, inflammation and vacuoles in hematopoietic cells represent the main features associated with VEXAS syndrome, a new prototype of autoinflammatory disorders genetically characterized by somatic mutation of the UBA1 gene which encodes the enzyme1-activating enzyme (E1) required for ubiquitin signaling. Described very recently, [...] Read more.
Fever, inflammation and vacuoles in hematopoietic cells represent the main features associated with VEXAS syndrome, a new prototype of autoinflammatory disorders genetically characterized by somatic mutation of the UBA1 gene which encodes the enzyme1-activating enzyme (E1) required for ubiquitin signaling. Described very recently, patients with VEXAS syndrome present a systemic autoinflammatory syndrome associated with hematological impairments, especially cytopenias whose pathophysiology is mainly non-elucidated. Initially diagnosed in elderly male patients, VEXAS syndrome was frequently associated with a diagnosis of myelodysplastic syndromes (MDS) leading the medical community to first consider VEXAS syndrome as a new subtype of MDS. However, since the first description of VEXAS patients in 2021, it appears from the multitude of case reports that MDS associated with VEXAS are different from the classically described MDS. Full article
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)
►▼ Show Figures

Figure 1

23 pages, 3652 KiB  
Review
Myelodysplastic Syndrome: Diagnosis and Screening
by Francisco P. Tria IV, Daphne C. Ang and Guang Fan
Diagnostics 2022, 12(7), 1581; https://doi.org/10.3390/diagnostics12071581 - 29 Jun 2022
Cited by 9 | Viewed by 4480
Abstract
Myelodysplastic syndromes (MDS) are heterogeneous groups of clonal myeloid disorders characterized by unexplained persistent peripheral blood (PB) cytopenia(s) of one or more of the hematopoietic lineages, or bone marrow (BM) morphologic dysplasia in hematopoietic cells, recurrent genetic abnormalities, and an increased risk of [...] Read more.
Myelodysplastic syndromes (MDS) are heterogeneous groups of clonal myeloid disorders characterized by unexplained persistent peripheral blood (PB) cytopenia(s) of one or more of the hematopoietic lineages, or bone marrow (BM) morphologic dysplasia in hematopoietic cells, recurrent genetic abnormalities, and an increased risk of progression to acute myeloid leukemia (AML). In the past several years, diagnostic, prognostic, and therapeutic approaches have substantially improved with the development of Next Generation Sequencing (NGS) diagnostic testing and new medications. However, there is no single diagnostic parameter specific for MDS, and correlations with clinical information, and laboratory test findings are needed to reach the diagnosis. Full article
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)
►▼ Show Figures

Figure 1

11 pages, 3672 KiB  
Review
Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers
by Jaja Zhu, Sylvain Clauser, Nicolas Freynet and Valérie Bardet
Diagnostics 2022, 12(7), 1556; https://doi.org/10.3390/diagnostics12071556 - 26 Jun 2022
Cited by 9 | Viewed by 3179
Abstract
Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous [...] Read more.
Myelodysplastic syndromes (MDSs) are clonal hematopoietic diseases of the elderly, characterized by chronic cytopenia, ineffective and dysplastic hematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. Diagnosis on a complete blood count (CBC) can be challenging due to numerous other non-neoplastic causes of cytopenias. New generations of hematology analyzers provide cell population data (CPD) that can be exploited to reliably detect MDSs from a routine CBC. In this review, we first describe the different technologies used to obtain CPD. We then give an overview of the currently available data regarding the performance of CPD for each lineage in the diagnostic workup of MDSs. Adequate exploitation of CPD can yield very strong diagnostic performances allowing for faster diagnosis and reduction of time-consuming slide reviews in the hematology laboratory. Full article
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)
►▼ Show Figures

Figure 1

Other

Jump to: Review

10 pages, 2151 KiB  
Guidelines
Perls’ Stain Guidelines from the French-Speaking Cellular Hematology Group (GFHC)
by Camille Lours, Laurane Cottin, Margaux Wiber, Valérie Andrieu, Véronique Baccini, Lucile Baseggio, Chantal Brouzes, Bernard Chatelain, Sylvie Daliphard, Odile Fenneteau, Franck Geneviève, Sandrine Girard, Vincent Leymarie, Karim Maloum, Jean-Baptiste Rieu, Gérard Sebahoun, Isabelle Sudaka, Xavier Troussard, Orianne Wagner-Ballon, Soraya Wuilleme, Valérie Bardet and Jean-François Lesesveadd Show full author list remove Hide full author list
Diagnostics 2022, 12(7), 1698; https://doi.org/10.3390/diagnostics12071698 - 12 Jul 2022
Cited by 2 | Viewed by 3145
Abstract
In order to standardize cellular hematology practices, the French-speaking Cellular Hematology Group (Groupe Francophone d’Hématologie Cellulaire, GFHC) focused on Perls’ stain. A national survey was carried out, leading to the proposal of recommendations on insoluble iron detection and quantification in bone marrow. The [...] Read more.
In order to standardize cellular hematology practices, the French-speaking Cellular Hematology Group (Groupe Francophone d’Hématologie Cellulaire, GFHC) focused on Perls’ stain. A national survey was carried out, leading to the proposal of recommendations on insoluble iron detection and quantification in bone marrow. The criteria presented here met with a “strong professional agreement” and follow the suggestions of the World Health Organization’s classification of hematological malignancies. Full article
(This article belongs to the Special Issue Myelodysplastic Syndrome: Diagnosis and Screening)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-8
Back to TopTop